{
    "id": 3338,
    "fullName": "ERBB2 L755S",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) L755S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755S results in increased phosphorylation of Erbb2 (Her2), activation of downstream signaling, is transforming in cell culture (PMID: 29967253, PMID: 31588020), and is associated with resistance to Erbb2 (Her2)-targeted therapies (PMID: 22046346, PMID: 28487443).",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                },
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11774,
                    "pubMedId": 29967253,
                    "title": "High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967253"
                },
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "L755S",
    "createDate": "02/25/2015",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 170597,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39723967T>C",
        "cDna": "c.2264T>C",
        "protein": "p.L755S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2035,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 622,
                "therapyName": "AEE788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20535,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarloxotinib (TRLX) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20377,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13221,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1 patient, partial response in 1 patient, stable disease in 2 patients, and progressive disease in 4 patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3036,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11640,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9679,
                    "pubMedId": 28679771,
                    "title": "Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679771"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7087,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Imbruvica (ibrutinib) in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20863,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) treatment resulted in increased tumor growth compared to vehicle control in cell line xenograft models of colorectal cancer harboring ERBB2 (HER2) L755S (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 967,
                "therapyName": "XL647",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13256,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 12.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21058,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) and Pictilisib (GDC-0941) synergistically inhibited viability of transformed breast epithelial cells expressing ERBB2 L755S in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 9545,
                "therapyName": "Lapatinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21059,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited viability of transformed breast epithelial cells expressing ERBB2 L755S in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 5011,
                "therapyName": "Neratinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20399,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7096,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7084,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21060,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) and Pictilisib (GDC-0941) synergistically inhibited viability of transformed breast epithelial cells expressing ERBB2 L755S in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 9546,
                "therapyName": "Neratinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21052,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed breast epithelial cells expressing ERBB2 (HER2) L755S were resistant to Nerlynx (neratinib) in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2037,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nerlynx (neratinib) resulted in growth inhibition in transformed human breast cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 23220880).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20862,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not significantly inhibit tumor growth compared to vehicle control in cell line xenograft models of colorectal cancer harboring ERBB2 (HER2) L755S (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed breast epithelial cells expressing ERBB2 (HER2) L755S were resistant to Tykerb (lapatinib) in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Pyrotinib in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 3082,
                "therapyName": "Pyrotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3035,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 2911,
                "therapyName": "EKI-285",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20861,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited viability of colorectal cancer cells harboring ERBB2 (HER2) L755S in culture, and reduced tumor size by 58% in a cell line xenograft model (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21056,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) and Selumetinib (AZD6244) synergistically inhibited viability of transformed breast epithelial cells expressing ERBB2 L755S in culture (PMID: 31135266).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 9544,
                "therapyName": "Lapatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18319,
                    "pubMedId": 31135266,
                    "title": "HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31135266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19134,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13194,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease in one and stable disease in another patient with biliary tract cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) treatment resulted in reduced tumor size and improved clinical performance for 11 months in a patient with triple-receptor negative breast cancer which harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) and Xeloda (capecitabine) combination treatment resulted in continued clinical performance improvement following progression on Neratinib (HKI-272) monotherapy in a patient with triple-receptor negative breast cancer that harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification, and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9333,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",
            "molecularProfile": {
                "id": 26822,
                "profileName": "APC Q1429fs BRAF N581S ERBB2 L755S"
            },
            "therapy": {
                "id": 4970,
                "therapyName": "Fluorouracil + Leucovorin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1996,
                "name": "rectum adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7088,
                    "pubMedId": 27626067,
                    "title": "Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626067"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Perjeta (pertuzumab) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture, and inhibited tumor growth in xenograft models (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12361,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16387,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) L755S, and breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 (HER2) L755S demonstrated sensitivity to Nerlynx (neratinib) in culture (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12355,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12359,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of ERBB2 (HER2) L755S resulted in decreased sensitivity to treatment with Kadcyla (trastuzumab emtansine) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition of ERBB2 (HER2) signaling and proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Tykerb (lapatinib) (PMID: 30301790).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12351,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443).",
            "molecularProfile": {
                "id": 28680,
                "profileName": "ERBB2 L755S ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10339,
                    "pubMedId": 28487443,
                    "title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28487443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13214,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) L755S, R1153*, and V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29029,
                "profileName": "ERBB2 L755S ERBB2 V777L ERBB2 R1153*"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15827,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ESR1)-positive cell line harboring ERBB2 (HER2) L755S demonstrated resistance to Faslodex (fulvestrant) in culture, and treatment with Faslodex (fulvestrant) prevented tumor growth, but did not induce regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15750,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15974,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, treatment with the combination of Nerlynx (neratinib) and Faslodex (fulvestrant) inhibited growth and reduced invasive behavior of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, to a greater degree than either agent alone, and resulted in tumor regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15838,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15976,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, resulting in growth inhibition (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15754,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15980,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15979,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, resulting in growth inhibition (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring ERBB2 (HER2) L755S and PIK3CA H1047R demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35136,
                "profileName": "ERBB2 L755S PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Nerlynx (neratinib) worked synergistically to inhibit viability of a breast cancer cell line harboring ERBB2 (HER2) L755S and PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35136,
                "profileName": "ERBB2 L755S PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3151,
            "profileName": "ERBB2 L755S",
            "profileTreatmentApproaches": [
                {
                    "id": 4480,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 L755S"
                },
                {
                    "id": 4479,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 L755S"
                }
            ]
        },
        {
            "id": 14286,
            "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26822,
            "profileName": "APC Q1429fs BRAF N581S ERBB2 L755S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28680,
            "profileName": "ERBB2 L755S ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29029,
            "profileName": "ERBB2 L755S ERBB2 V777L ERBB2 R1153*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31190,
            "profileName": "ERBB2 L755S ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35136,
            "profileName": "ERBB2 L755S PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170596,
            "transcript": "NM_001005862",
            "gDna": "chr17:g.39724771_39724772delCTinsAG",
            "cDna": "c.2263_2264delCTinsAG",
            "protein": "p.L755S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170597,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39723967T>C",
            "cDna": "c.2264T>C",
            "protein": "p.L755S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170598,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39723967T>C",
            "cDna": "c.2264T>C",
            "protein": "p.L755S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}